A Phase 1/2 interventional study of niraparib and pembrolizumab in Neoplasms, Triple Negative Breast Cancer and Ovarian Cancer, sponsored by Tesaro, Inc.. Completed at 30 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-01.
Sponsored by Tesaro, Inc. (part of GlaxoSmithKline) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This Phase 1/2 study will evaluate the safety and efficacy of combination treatment with niraparib and pembrolizumab (MK-3475) in patients with advanced or metastatic triple-negative breast cancer or recurrent ovarian cancer. (KEYNOTE-162)
10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.
This study's enrollment of 122 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Tesaro, Inc. is the lead sponsor of 33 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.
First submitted before Tesaro, Inc. became part of GlaxoSmithKline.
Counted across the registry records on this site, refreshed daily.
Main Inclusion Criteria:
Patient has proven advanced (unresectable) or cancer as outlined below according to study phase and disease type:
Phase 1 patients (breast or ovarian cancer)
Phase 2 patients (breast or ovarian cancer)
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase 1: Dose-escalation: ascending doses of niraparib up to 300mg/day orally (PO) on Days 1-21 and pembrolizumab 200mg intravenously (IV) on Day 1 of each 21-day cycle Phase 2: niraparib (recommended Phase 2 dose) in combination with pembrolizumab 200mg IV on Day 1 of each 21-day cycle
Drug: niraparib · Biological: pembrolizumab
Phase 1: Number of Participants Reporting Dose-Limiting Toxicities (DLTs)
DLTs are defined as: Any treatment-related Grade \>=3 non-hematologic clinical (non-laboratory) adverse event (AE); Any treatment-related Grade 3 or Grade 4 non-hematologic laboratory (lab) abnormality if Medical intervention is required to treat the participant or the abnormality leads to hospitalization or the abnormality persists for \>=7 days; Any treatment-related hematologic toxicity specifically defined as: Thrombocytopenia Grade 4 for \>=7 days, or Grade 3 or 4 associated with bleeding or requiring platelet transfusion, Neutropenia Grade 4 for \>=7 days, or Grade 3 or 4 associated with infection or febrile neutropenia, Anemia Grade 4, or Grade 3 or 4 requiring blood transfusion; Any treatment-related AE leading to niraparib dose interruption per the following criteria: A dose interruption for a non-DLT lab abnormality lasting \>=14 days, A dose in interruption per dose modification rules for non-hematologic AE leading to \<80 percent (%) of an intended dose being administered.
Time frame: During Cycle 1, ie, during the first 21 days of treatment
Phase 2: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1
ORR is defined as the percentage of participants with a confirmed best overall response of Complete Response (CR) or Partial Response (PR), RECIST v1.1 for target lesions as assessed by the Investigator. CR is defined as disappearance of all target lesions, Any pathological lymph nodes must be \<10 millimeters (mm) in the short axis; PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the Baseline sum diameters.
Time frame: Up to 40 weeks
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event was any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. TEAEs were any new AE that begins, or any pre-existing condition that worsens in severity, after at least 1 dose of study treatment has been administered.
Time frame: Up to a maximum of 22 months
Phase 2: Number of Participants With TEAEs
An adverse event was any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. TEAEs were any new AE that begins, or any pre-existing condition that worsens in severity, after at least 1 dose of study treatment has been administered.
Time frame: Up to a maximum of 54 months
Phase 2: Overall Response Rate (ORR) as Measured by Immune-related RECIST (irRECIST)
ORR by irRECIST is defined as the percentage of participants with a confirmed best overall response of CR or PR using irRECIST. Immune related complete response (irCR) is defined as at least two radiographic determinations of CR, at least 4 weeks apart and before Immune related progressive disease (irPD - defined as at least two consecutive radiographic determinations of progressive disease \[PD\] at least 4 weeks apart) at least 4 weeks apart. Immune related partial response (irPR) defined as at least two radiographic determinations of PR or better at least 4 weeks apart and before irPD (and not qualifying for an irCR).
Time frame: Up to a maximum of 54 months
Phase 2: Duration of Response (DOR) as Measured by RECIST v1.1
DoR per RECIST v1.1 was defined as the time from first documented evidence of CR or PR until first documented disease progression per RECIST v1.1 based upon investigator assessment or death due to any cause, whichever occurs first, among participants who demonstrated CR or PR as the best overall response per RECIST v1.1. CR is defined as disappearance of all target lesions. Any pathological lymph nodes must be \<10 millimeters (mm) in the short axis. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the Baseline sum diameters.
Time frame: Up to a maximum of 54 months
Phase 2: DOR as Measured by irRECIST
DOR was defined as the time from the initial response (irCR, irPR or irSD) to progression or death, whichever occurs first. Response was to be assessed using the irRECIST. Immune related complete response (irCR) is at least two radiographic determinations of CR at least 4 weeks apart and before Immune related progressive disease (irPD - defined as at least two consecutive radiographic determinations of PD at least 4 weeks apart) at least 4 weeks apart. Immune related partial response (irPR) defined as at least two radiographic determinations of PR or better at least 4 weeks apart and before irPD (and not qualifying for an irCR).
Time frame: Up to a maximum of 54 months
Phase 2: Disease Control Rate (DCR) as Measured by RECIST v1.1
DCR is defined as the percentage of participants who achieved a CR or PR or stable disease (SD) using RECIST (v1.1) as assessed by the investigator.
Time frame: Up to 40 weeks
Phase 2: DCR as Measured by irRECIST
DCR is percentage of participants achieving best overall response of confirmed irCR, irPR, or immune-related stable disease (irSD) (lasting at least 5 weeks), according to irRECIST from the first dose date until disease progression/recurrence.
Time frame: Up to a maximum of 54 months
Phase 2: Progression Free Survival (PFS) as Measured by RECIST v1.1
PFS is defined as the time from first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression based on the time of first documentation of disease progression per RECIST v1.1. Progression is defined using RECIST v1.1 as a 20% increase in the sum of the diameter of target lesions or unequivocal progression of existing non-target lesions or the appearance of one or more new lesions.
Time frame: Up to a maximum of 54 months
Phase 2: PFS as Measured by irRECIST
Progression free survival is defined as the duration of time from the date of study enrollment until time of disease relapse, disease progression, or death, whichever comes first. Progression was to be assessed using the Immune Related Response Evaluation Criteria in Solid Tumors (irRECIST). Immune related progressive disease (irPD) is defined as at least two consecutive radiographic determinations of progressive disease (PD - e.g., appearance of one or more new lesions) at least 4 weeks apart).
Time frame: Up to a maximum of 54 months
Phase 2: Overall Survival (OS)
OS is defined as the time from date of first dose of study treatment to the date of death by any cause.
Time frame: Up to a maximum of 54 months
Phase 1: Area Under the Plasma Concentration-time Curve From Time 0 (Predose) to 24 Hours Post Dose (AUC [0-24]) of Niraparib
Blood samples were collected at indicated time points. Pharmacokinetic (PK) analysis of Niraparib was conducted using standard non-compartmental analysis.
Time frame: Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)
Phase 1: AUC (0-24) of Major Metabolite of Niraparib (M1)
Blood samples were collected at indicated time points. Pharmacokinetic analysis of major metabolite of Niraparib (M1) was conducted using standard non-compartmental analysis.
Time frame: Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)
Phase 1: Minimum Observed Plasma Concentration (Cmin) and Maximum Observed Plasma Concentration (Cmax) of Niraparib
Blood samples were collected at indicated time points. Pharmacokinetic analysis of Niraparib was conducted using standard non-compartmental analysis.
Time frame: Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)
Phase 1: Cmin and Cmax of Major Metabolite of Niraparib (M1)
Blood samples were collected at indicated time points. Pharmacokinetic analysis of major metabolite of Niraparib (M1) was conducted using standard non-compartmental analysis.
Time frame: Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)
Phase 1: Apparent Oral Clearance (CL/F) of Niraparib
Blood samples were planned to be collected for to determine CL/F of Niraparib.
Time frame: Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)
Phase 1: Apparent Oral Clearance (CL/F) of Major Metabolite of Niraparib (M1)
Blood samples were planned to be collected for to determine CL/F of major metabolite (M1) of Niraparib.
Time frame: Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)
Phase 1: Volume of Distribution (Vz/F) of Niraparib
Blood samples were planned to be collected for to determine Vz/F of Niraparib.
Time frame: Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)
Phase 1: Volume of Distribution (Vz/F) of Major Metabolite of Niraparib (M1)
Blood samples were planned to be collected for to determine Vz/F of major metabolite (M1) of Niraparib.
Time frame: Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)
Phase 1: AUC at Steady State (AUC,ss) of Niraparib
Blood samples were collected at indicated time points. Pharmacokinetic analysis of Niraparib was conducted using standard non-compartmental analysis.
Time frame: Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 2 Day 1 (each cycle of 21 days)
Phase 1: AUC,ss of Major Metabolite of Niraparib (M1)
Blood samples were collected at indicated time points. Pharmacokinetic analysis of major metabolite of Niraparib (M1) was conducted using standard non-compartmental analysis.
Time frame: Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 2 Day 1 (each cycle of 21 days)
Phase 1: Minimum Observed Plasma Concentration at Steady State (Cmin,ss) and Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of Niraparib
Blood samples were collected at indicated time points. Pharmacokinetic analysis of Niraparib was conducted using standard non-compartmental analysis.
Time frame: Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 2 Day 1 (each cycle of 21 days)
Phase 1: Cmin,ss and Cmax,ss of Major Metabolite of Niraparib (M1)
Blood samples were collected at indicated time points. Pharmacokinetic analysis of major metabolite of Niraparib (M1) was conducted using standard non-compartmental analysis.
Time frame: Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 2 Day 1(each cycle of 21 days)
Phase 2: Plasma Concentrations of Niraparib
Blood samples were collected by sparse PK sampling to analyze plasma concentration of Niraparib.
Time frame: Pre-dose and 2 Hours post-dose on Cycle 1 Day 1; Pre-dose and 2 Hours post-dose on Cycle 2 Day 1(each cycle of 21 days)
Phase 2: Plasma Concentrations of Major Metabolite of Niraparib (M1)
Blood samples were collected by sparse PK sampling to analyze plasma concentration of major metabolite of Niraparib (M1).
Time frame: Pre-dose and 2 Hours post-dose on Cycle 1 Day 1; Pre-dose and 2 Hours post-dose on Cycle 2 Day 1 (each cycle of 21 days)
This was a multicenter study conducted in the United States.
| Milestone | Phase 1: Niraparib 200 mg + Pembrolizumab | Phase 1: Niraparib 300 mg + Pembrolizumab | Phase 2 OC: Niraparib 200mg + Pembrolizumab | Phase 2 TNBC: Niraparib 200mg + Pembrolizumab |
|---|---|---|---|---|
| Started | 7 | 7 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 7 | 7 | 0 | 0 |
| Withdrew: Death | 5 | 5 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 1 | 0 | 0 |
| Withdrew: Radiologic disease progression | 0 | 1 | 0 | 0 |
| Milestone | Phase 1: Niraparib 200 mg + Pembrolizumab | Phase 1: Niraparib 300 mg + Pembrolizumab | Phase 2 OC: Niraparib 200mg + Pembrolizumab | Phase 2 TNBC: Niraparib 200mg + Pembrolizumab |
|---|---|---|---|---|
| Started | 0 | 0 | 53 | 55 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 53 | 55 |
| Withdrew: Death | 0 | 0 | 30 | 42 |
| Withdrew: Lost to follow-up | 0 | 0 | 5 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 8 | 2 |
| Withdrew: Sponsor decision | 0 | 0 | 2 | 2 |
| Withdrew: Radiologic disease progression | 0 | 0 | 6 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
| Withdrew: Participant request | 0 | 0 | 2 | 1 |
| Withdrew: Participants went on rollover study | 0 | 0 | 0 | 4 |
DLTs are defined as: Any treatment-related Grade \>=3 non-hematologic clinical (non-laboratory) adverse event (AE); Any treatment-related Grade 3 or Grade 4 non-hematologic laboratory (lab) abnormality if Medical intervention is required to treat the participant or the abnormality leads to hospitalization or the abnormality persists for \>=7 days; Any treatment-related hematologic toxicity specifically defined as: Thrombocytopenia Grade 4 for \>=7 days, or Grade 3 or 4 associated with bleeding or requiring platelet transfusion, Neutropenia Grade 4 for \>=7 days, or Grade 3 or 4 associated with infection or febrile neutropenia, Anemia Grade 4, or Grade 3 or 4 requiring blood transfusion; Any treatment-related AE leading to niraparib dose interruption per the following criteria: A dose interruption for a non-DLT lab abnormality lasting \>=14 days, A dose in interruption per dose modification rules for non-hematologic AE leading to \<80 percent (%) of an intended dose being administered.
| Participants | Phase 1: Niraparib 200 mg + Pembrolizumab | Phase 1: Niraparib 300 mg + Pembrolizumab |
|---|---|---|
| Phase 1: Number of Participants Reporting Dose-Limiting Toxicities (DLTs) | 1 | 1 |
ORR is defined as the percentage of participants with a confirmed best overall response of Complete Response (CR) or Partial Response (PR), RECIST v1.1 for target lesions as assessed by the Investigator. CR is defined as disappearance of all target lesions, Any pathological lymph nodes must be \<10 millimeters (mm) in the short axis; PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the Baseline sum diameters.
| Percentage of participants | Phase 2 OC: Niraparib 200mg + Pembrolizumab | Phase 2 TNBC: Niraparib 200mg + Pembrolizumab |
|---|---|---|
| Phase 2: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 | 15.1 (7.7 to 25.6) | 18.2 (10.2 to 28.9) |
An adverse event was any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. TEAEs were any new AE that begins, or any pre-existing condition that worsens in severity, after at least 1 dose of study treatment has been administered.
| Participants | Phase 1: Niraparib 200 mg + Pembrolizumab | Phase 1: Niraparib 300 mg + Pembrolizumab |
|---|---|---|
| Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 7 | 7 |
An adverse event was any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. TEAEs were any new AE that begins, or any pre-existing condition that worsens in severity, after at least 1 dose of study treatment has been administered.
| Participants | Phase 2 OC: Niraparib 200 mg + Pembrolizumab | Phase 2 TNBC: Niraparib 200 mg + Pembrolizumab |
|---|---|---|
| Phase 2: Number of Participants With TEAEs | 53 | 54 |
ORR by irRECIST is defined as the percentage of participants with a confirmed best overall response of CR or PR using irRECIST. Immune related complete response (irCR) is defined as at least two radiographic determinations of CR, at least 4 weeks apart and before Immune related progressive disease (irPD - defined as at least two consecutive radiographic determinations of progressive disease \[PD\] at least 4 weeks apart) at least 4 weeks apart. Immune related partial response (irPR) defined as at least two radiographic determinations of PR or better at least 4 weeks apart and before irPD (and not qualifying for an irCR).
No measurements were reported for this outcome.
DoR per RECIST v1.1 was defined as the time from first documented evidence of CR or PR until first documented disease progression per RECIST v1.1 based upon investigator assessment or death due to any cause, whichever occurs first, among participants who demonstrated CR or PR as the best overall response per RECIST v1.1. CR is defined as disappearance of all target lesions. Any pathological lymph nodes must be \<10 millimeters (mm) in the short axis. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the Baseline sum diameters.
| Months | Phase 2 OC: Niraparib 200 mg + Pembrolizumab | Phase 2 TNBC: Niraparib 200 mg + Pembrolizumab |
|---|---|---|
| Phase 2: Duration of Response (DOR) as Measured by RECIST v1.1 | 14.4 (8.3 to 18.7) | 21.5 (8.4 to NA) |
DOR was defined as the time from the initial response (irCR, irPR or irSD) to progression or death, whichever occurs first. Response was to be assessed using the irRECIST. Immune related complete response (irCR) is at least two radiographic determinations of CR at least 4 weeks apart and before Immune related progressive disease (irPD - defined as at least two consecutive radiographic determinations of PD at least 4 weeks apart) at least 4 weeks apart. Immune related partial response (irPR) defined as at least two radiographic determinations of PR or better at least 4 weeks apart and before irPD (and not qualifying for an irCR).
No measurements were reported for this outcome.
DCR is defined as the percentage of participants who achieved a CR or PR or stable disease (SD) using RECIST (v1.1) as assessed by the investigator.
| Percentage of participants | Phase 2 OC: Niraparib 200mg + Pembrolizumab | Phase 2 TNBC: Niraparib 200mg + Pembrolizumab |
|---|---|---|
| Phase 2: Disease Control Rate (DCR) as Measured by RECIST v1.1 | 58.5 (46.3 to 70.0) | 41.8 (30.5 to 53.8) |
DCR is percentage of participants achieving best overall response of confirmed irCR, irPR, or immune-related stable disease (irSD) (lasting at least 5 weeks), according to irRECIST from the first dose date until disease progression/recurrence.
No measurements were reported for this outcome.
PFS is defined as the time from first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression based on the time of first documentation of disease progression per RECIST v1.1. Progression is defined using RECIST v1.1 as a 20% increase in the sum of the diameter of target lesions or unequivocal progression of existing non-target lesions or the appearance of one or more new lesions.
| Months | Phase 2 OC: Niraparib 200 mg + Pembrolizumab | Phase 2 TNBC: Niraparib 200 mg + Pembrolizumab |
|---|---|---|
| Phase 2: Progression Free Survival (PFS) as Measured by RECIST v1.1 | 3.4 (2.1 to 8.2) | 2.5 (1.4 to 6.4) |
Progression free survival is defined as the duration of time from the date of study enrollment until time of disease relapse, disease progression, or death, whichever comes first. Progression was to be assessed using the Immune Related Response Evaluation Criteria in Solid Tumors (irRECIST). Immune related progressive disease (irPD) is defined as at least two consecutive radiographic determinations of progressive disease (PD - e.g., appearance of one or more new lesions) at least 4 weeks apart).
No measurements were reported for this outcome.
OS is defined as the time from date of first dose of study treatment to the date of death by any cause.
| Months | Phase 2 OC: Niraparib 200 mg + Pembrolizumab | Phase 2 TNBC: Niraparib 200mg + Pembrolizumab |
|---|---|---|
| Phase 2: Overall Survival (OS) | 17.1 (7.9 to NA) | 9.4 (3.2 to 22.2) |
Blood samples were collected at indicated time points. Pharmacokinetic (PK) analysis of Niraparib was conducted using standard non-compartmental analysis.
| Hour*nanogram per milliliter | Phase 1: Niraparib 200 mg + Pembrolizumab | Phase 1: Niraparib 300 mg + Pembrolizumab |
|---|---|---|
| Phase 1: Area Under the Plasma Concentration-time Curve From Time 0 (Predose) to 24 Hours Post Dose (AUC [0-24]) of Niraparib | 6524.035 ± 2606.263 | 8855.687 ± 1415.318 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of major metabolite of Niraparib (M1) was conducted using standard non-compartmental analysis.
| Hour*nanogram per milliliter | Phase 1: Niraparib 200 mg + Pembrolizumab | Phase 1: Niraparib 300 mg + Pembrolizumab |
|---|---|---|
| Phase 1: AUC (0-24) of Major Metabolite of Niraparib (M1) | 4886.115 ± 975.011 | 11076.538 ± 6691.358 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of Niraparib was conducted using standard non-compartmental analysis.
| Nanogram per milliliter | Phase 1: Niraparib 200 mg + Pembrolizumab | Phase 1: Niraparib 300 mg + Pembrolizumab |
|---|---|---|
| Cmin | 174.00 ± 84.922 | 205.63 ± 196.714 |
| Cmax | 546.0 ± 195.95 | 711.3 ± 189.98 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of major metabolite of Niraparib (M1) was conducted using standard non-compartmental analysis.
| Nanogram per milliliter | Phase 1: Niraparib 200 mg + Pembrolizumab | Phase 1: Niraparib 300 mg + Pembrolizumab |
|---|---|---|
| Cmin | 42.114 ± 42.765 | 46.677 ± 45.343 |
| Cmax | 340.14 ± 89.356 | 491.66 ± 226.122 |
Blood samples were planned to be collected for to determine CL/F of Niraparib.
| Liters per hour | Phase 1: Niraparib 200 mg + Pembrolizumab | Phase 1: Niraparib 300 mg + Pembrolizumab |
|---|---|---|
| Phase 1: Apparent Oral Clearance (CL/F) of Niraparib | NA ± NA | NA ± NA |
Blood samples were planned to be collected for to determine CL/F of major metabolite (M1) of Niraparib.
| Liters per hour | Phase 1: Niraparib 200 mg + Pembrolizumab | Phase 1: Niraparib 300 mg + Pembrolizumab |
|---|---|---|
| Phase 1: Apparent Oral Clearance (CL/F) of Major Metabolite of Niraparib (M1) | NA ± NA | NA ± NA |
Blood samples were planned to be collected for to determine Vz/F of Niraparib.
| Liters | Phase 1: Niraparib 200 mg + Pembrolizumab | Phase 1: Niraparib 300 mg + Pembrolizumab |
|---|---|---|
| Phase 1: Volume of Distribution (Vz/F) of Niraparib | NA ± NA | NA ± NA |
Blood samples were planned to be collected for to determine Vz/F of major metabolite (M1) of Niraparib.
| Liters | Phase 1: Niraparib 200 mg + Pembrolizumab | Phase 1: Niraparib 300 mg + Pembrolizumab |
|---|---|---|
| Phase 1: Volume of Distribution (Vz/F) of Major Metabolite of Niraparib (M1) | NA ± NA | NA ± NA |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of Niraparib was conducted using standard non-compartmental analysis.
| Hour*nanograms per milliliter | Phase 1: Niraparib 200 mg + Pembrolizumab | Phase 1: Niraparib 300 mg + Pembrolizumab |
|---|---|---|
| Phase 1: AUC at Steady State (AUC,ss) of Niraparib | 27396.910 ± 15097.186 | 30799.742 ± 9868.734 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of major metabolite of Niraparib (M1) was conducted using standard non-compartmental analysis.
| Hour*nanograms per milliliter | Phase 1: Niraparib 200 mg + Pembrolizumab | Phase 1: Niraparib 300 mg + Pembrolizumab |
|---|---|---|
| Phase 1: AUC,ss of Major Metabolite of Niraparib (M1) | 32878.205 ± NA | 127430.14 ± NA |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of Niraparib was conducted using standard non-compartmental analysis.
| Nanograms per milliliter | Phase 1: Niraparib 200 mg + Pembrolizumab | Phase 1: Niraparib 300 mg + Pembrolizumab |
|---|---|---|
| Cmin,ss | 878.75 ± 651.122 | 849.00 ± 194.841 |
| Cmax,ss | 1585.5 ± 812.63 | 1606.7 ± 261.02 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of major metabolite of Niraparib (M1) was conducted using standard non-compartmental analysis.
| Nanograms per milliliter | Phase 1: Niraparib 200 mg + Pembrolizumab | Phase 1: Niraparib 300 mg + Pembrolizumab |
|---|---|---|
| Cmin,ss | 1410.000 ± 207.686 | 3280.000 ± 1460.411 |
| Cmax,ss | 2177.50 ± 475.000 | 4213.33 ± 1515.333 |
Blood samples were collected by sparse PK sampling to analyze plasma concentration of Niraparib.
| Nanograms per milliliter | Phase 2 OC: Niraparib 200 mg + Pembrolizumab | Phase 2 TNBC: Niraparib 200mg + Pembrolizumab |
|---|---|---|
| Cycle 1 Day 1: Predose | 0.000 ± 0.000 | 0.000 ± 0.000 |
| Cycle 1 Day 1; 2 hours post dose | 315.979 ± 199.798 | 302.642 ± 267.128 |
| Cycle 2 Day 1; Predose | 441.978 ± 229.948 | 510.154 ± 263.634 |
| Cycle 2; Day 1; 2 hours post dose | 764.500 ± 370.140 | 884.185 ± 508.607 |
Blood samples were collected by sparse PK sampling to analyze plasma concentration of major metabolite of Niraparib (M1).
| Nanograms per milliliter | Phase 2 OC: Niraparib 200 mg + Pembrolizumab | Phase 2 TNBC: Niraparib 200mg + Pembrolizumab |
|---|---|---|
| Cycle 1 Day 1; Predose | 0.000 ± 0.000 | 0.000 ± 0.000 |
| Cycle 1 Day1; 2 hours post dose | 116.666 ± 89.108 | 84.875 ± 92.206 |
| Cycle 2 Day 1; Predose | 1278.926 ± 625.932 | 1070.923 ± 648.225 |
| Cycle 2 Day 1; 2 hours post dose | 1500.143 ± 976.572 | 1205.444 ± 858.698 |
Collected over All-cause mortality, serious adverse events (SAE) and non-serious adverse events (non-SAEs) were collected up to a maximum of 22 months in Phase 1 and up to a maximum of 54 months in Phase 2 of the study. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: Niraparib 200 mg + Pembrolizumab | 5/7 (71.4%) | 6/7 (85.7%) | 7/7 (100%) |
| Phase 1: Niraparib 300 mg + Pembrolizumab | 5/7 (71.4%) | 4/7 (57.1%) | 7/7 (100%) |
| Phase 2 OC: Niraparib 200 mg + Pembrolizumab | 30/53 (56.6%) | 22/53 (41.5%) | 52/53 (98.1%) |
| Phase 2 TNBC: Niraparib 200 mg + Pembrolizumab | 42/55 (76.4%) | 24/55 (43.6%) | 54/55 (98.2%) |
| Event | Phase 1: Niraparib 200 mg + Pembrolizumab | Phase 1: Niraparib 300 mg + Pembrolizumab | Phase 2 OC: Niraparib 200 mg + Pembrolizumab | Phase 2 TNBC: Niraparib 200 mg + Pembrolizumab |
|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 1/7 | 3/7 | 2/53 | 4/55 |
| Abdominal painGastrointestinal disorders | 2/7 | 0/7 | 1/53 | 0/55 |
| NauseaGastrointestinal disorders | 2/7 | 1/7 | 2/53 | 0/55 |
| AnaemiaBlood and lymphatic system disorders | 1/7 | 0/7 | 2/53 | 1/55 |
| NeutropeniaBlood and lymphatic system disorders | 1/7 | 0/7 | 1/53 | 0/55 |
| PancytopeniaBlood and lymphatic system disorders | 0/7 | 1/7 | 0/53 | 1/55 |
| Abdominal distensionGastrointestinal disorders | 1/7 | 0/7 | 0/53 | 0/55 |
| AscitesGastrointestinal disorders | 1/7 | 0/7 | 0/53 | 0/55 |
| ColitisGastrointestinal disorders | 1/7 | 0/7 | 0/53 | 0/55 |
| Obstruction gastricGastrointestinal disorders | 1/7 | 0/7 | 0/53 | 0/55 |
| Event | Phase 1: Niraparib 200 mg + Pembrolizumab | Phase 1: Niraparib 300 mg + Pembrolizumab | Phase 2 OC: Niraparib 200 mg + Pembrolizumab | Phase 2 TNBC: Niraparib 200 mg + Pembrolizumab |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 5/7 | 5/7 | 19/53 | 24/55 |
| ConstipationGastrointestinal disorders | 5/7 | 2/7 | 28/53 | 24/55 |
| NauseaGastrointestinal disorders | 4/7 | 4/7 | 32/53 | 34/55 |
| FatigueGeneral disorders | 4/7 | 3/7 | 32/53 | 30/55 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/7 | 4/7 | 14/53 | 14/55 |
| VomitingGastrointestinal disorders | 4/7 | 2/7 | 21/53 | 13/55 |
| HyponatraemiaMetabolism and nutrition disorders | 4/7 | 3/7 | 6/53 | 6/55 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/7 | 4/7 | 11/53 | 20/55 |
| Abdominal distensionGastrointestinal disorders | 3/7 | 0/7 | 5/53 | 3/55 |
| Abdominal painGastrointestinal disorders | 3/7 | 0/7 | 13/53 | 8/55 |
The Baseline analysis Population consisted of all participants who received at least one dose of study medication.
| Age, Categorical(Participants) | Phase 1: Niraparib 200 mg + Pembrolizumab | Phase 1: Niraparib 300 mg + Pembrolizumab | Phase 2 OC: Niraparib 200mg + Pembrolizumab | Phase 2 TNBC: Niraparib 200mg + Pembrolizumab | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 4 | 37 | 47 | 92 |
| >=65 years | 3 | 3 | 16 | 8 | 30 |
| Sex: Female, Male(Participants) | Phase 1: Niraparib 200 mg + Pembrolizumab | Phase 1: Niraparib 300 mg + Pembrolizumab | Phase 2 OC: Niraparib 200mg + Pembrolizumab | Phase 2 TNBC: Niraparib 200mg + Pembrolizumab | Total |
|---|---|---|---|---|---|
| Female | 7 | 7 | 53 | 55 | 122 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1: Niraparib 200 mg + Pembrolizumab | Phase 1: Niraparib 300 mg + Pembrolizumab | Phase 2 OC: Niraparib 200mg + Pembrolizumab | Phase 2 TNBC: Niraparib 200mg + Pembrolizumab | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 3 | 3 | 7 |
| Not Hispanic or Latino | 6 | 6 | 50 | 51 | 113 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Phase 1: Niraparib 200 mg + Pembrolizumab | Phase 1: Niraparib 300 mg + Pembrolizumab | Phase 2 OC: Niraparib 200mg + Pembrolizumab | Phase 2 TNBC: Niraparib 200mg + Pembrolizumab | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 3 | 2 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 8 | 9 |
| White | 7 | 7 | 46 | 43 | 103 |
| More than one race | NA | NA | NA | NA | NA |
| Unknown or Not Reported | 0 | 0 | 3 | 2 | 5 |
| Region of Enrollment(Participants) | Phase 1: Niraparib 200 mg + Pembrolizumab | Phase 1: Niraparib 300 mg + Pembrolizumab | Phase 2 OC: Niraparib 200mg + Pembrolizumab | Phase 2 TNBC: Niraparib 200mg + Pembrolizumab | Total |
|---|---|---|---|---|---|
| United States | 7 | 7 | 53 | 55 | 122 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2016 to primary completion in May 2018, 24 months.
Results were first posted in Feb 2020, 1 year 8 months after primary completion.
Of 194 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's 24 months is below that.
Counting every sponsor, half of 296 studies reached it within 60 months; a quarter within 39 and three quarters within 89.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Niraparib